Active ingredients

Cannabis contains over 100 cannabinoids and over 300 other chemical compounds that affect various systems in the body. These affect health and disease states. The chemical components of cannabis not only affect the endocannabinoid system, but a multitude of units in our body.


Research shows that the effects of phytocannabinoids could be influenced by scents produced by the cannabis plant called terpenes. This interaction would lead to the entourage effect. This approach states that cannabinoids work better when taken in conjunction with a range of other cannabinoids, terpenes, flavonoids and compounds found in cannabis than when taken as isolated agents.

Tetrahydrocannabinol (THC)

THC is an intoxicating and psychoactive cannabinoid. It comes in two forms: delta-9-THC and delta-8-THC. Delta-9-THC is the most well-known cannabinoid found in the cannabis plant and is commonly referred to colloquially as THC. It can produce a variety of sensory and mental effects, such as: B. light reverie, a sense of balance, increased sensitivity, but also therapeutic effects. While THC is not solely responsible for the psychoactive effects of cannabis, it is the main psychoactive compound. THC is only activated when it goes through a heat process. In doing so, it is converted from its original chemical structure THCA (acidic form) to THC. THC binds and activates the CB1 receptors, found primarily in the central nervous system, leading to the well-known “high” and other psychological effects.

Cannabidiol (CBD)

Cannabidiol (CBD) is a well-known cannabinoid today and is the focus of much medical research. CBD is considered "non-psychoactive" but does alter consciousness to some extent, as evidenced by its effectiveness on anxiety. After THC, cannabidiol is the second most abundant cannabinoid in the hemp plant. CBD is created by heating or decarboxylating cannabidiol acid (CBDA). Most cannabis strains have lower concentrations of CBD than THC. CBD has many potential therapeutic benefits that consumers continue to endorse.

The effects of CBD on the brain and body are quite complicated. It is most likely that the beneficial effects of CBD occur through multiple biological pathways, rather than just one process. More research is needed to fully understand the mechanisms by which CBD relieves conditions such as seizures.

In contrast to many active pharmaceutical ingredients with only one mechanism of action, CBD is a medical miracle weapon with a convincing side effect profile and great therapeutic potential.


Terpenes are the main components of the essential oils found in various strains of cannabis. These substances are responsible for the characteristic smell and taste notes. Terpenes are produced by various plants, especially conifers. Many of the terpenes are related to the plants defense mechanisms against plant pests and the environment. The word terpene has its origin in turpentine, which is the sap of cut down trees or distilled from wood.
Turpentine was used in ancient Chinese medicine to treat toothache and respiratory problems. Terpenes are very volatile and will “vaporize” quickly at moderate temperatures. Because of this, the air smells fresher in the morning, as plants then release their maximum concentration of terpenes before being evaporated by the sun throughout the day.
The main terpenes in cannabis are a-pinene (also found in pine needles and rosemary), linalool (also found in lavender and frankincense), beta-caryophyllene (also found in black pepper), myrcene (also found in hops), and limonene, which is smells like lemons and is contained in citrus fruits.

Like cannabinoids, terpenes also have properties that underscore a plants medicinal value. Terpenes give fruits, flowers, vegetables, and spices their pleasant smell. These substances also have anti-cancer, anti-inflammatory, anxiolytic, sleep-inducing and mood-enhancing therapeutic properties.



1. Light, M. K., A. Orens, B. Lewandowski, and T. P. Market size and demand for marijuana in Colorado. (2014).

2. Ilgen, M. A. et al. Characteristics of adults seeking medical marijuana certification. Drug Alcohol Depend. 132, 654–659 (2013).

3. Boehnke, K. F., Litinas, E. & Clauw, D. J. Medical Cannabis Use Is Associated with Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients with Chronic Pain. J. Pain 17, 739–744 (2016).

4. Whiting, P. F. et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA - J. Am. Med. Assoc. 313, 2456–2473 (2015).

5. Ware, M. A. et al. Smoked cannabis for chronic neuropathic pain: A randomized controlled trial. Cmaj 182, (2010).

6. Mechtler, L. L., Gengo, F. M. & Bargnes, V. H. Cannabis and Migraine: It’s Complicated. Curr. Pain Headache Rep. 25, 1–13 (2021).

7. Rhyne, D. N., Anderson, S. L., Gedde, M. & Borgelt, L. M. Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population. Pharmacotherapy 36, 505–510 (2016).

8. Russo, E. Cannabis for migraine treatment: The once and future prescription? An historical and scientific review. Pain 76, 3–8 (1998).

9. Cuttler, C., Spradlin, A., Cleveland, M. J. & Craft, R. M. Short- and Long-Term Effects of Cannabis on Headache and Migraine. J. Pain 21, 722–730 (2020).

10. Baron, E. P. Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache 58, 1139–1186 (2018).

11. Serpell, M. et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur. J. Pain (United Kingdom) 18, 999–1012 (2014).

12. Hoch, E. et al. How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. Eur. Arch. Psychiatry Clin. Neurosci. 269, 87–105 (2019).

13. Bachhuber, M., Arnsten, J. H. & Wurm, G. Use of Cannabis to Relieve Pain and Promote Sleep by Customers at an Adult Use Dispensary. J. Psychoactive Drugs 51, 400–404 (2019).

14. Shannon, S., Lewis, N., Lee, H. & Hughes, S. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm. J. 23, 18–041 (2019).

15. Piper, B. J. et al. Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J. Psychopharmacol. 31, 569–575 (2017).

16. Corroon, J. M., Mischley, L. K. & Sexton, M. Cannabis as a substitute for prescription drugs - A cross-sectional study. J. Pain Res. 10, 989–998 (2017).

17. Duran, M. et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br. J. Clin. Pharmacol. 70, 656–663 (2010).

18. Hernandez, S. L., Sheyner, I., Stover, K. T. & Stewart, J. T. Dronabinol Treatment of Refractory Nausea and Vomiting Related to Peritoneal Carcinomatosis. Am. J. Hosp. Palliat. Med. 32, 5–7 (2015).

19. Merriman, A. R. & Oliak, D. A. Use of medical marijuana for treatment of severe intractable nausea after laparoscopic Roux-en-Y gastric bypass surgery. Surg. Obes. Relat. Dis. 4, 550–551 (2008).

20. Westfall, R. E., Janssen, P. A., Lucas, P. & Capler, R. Reprint of: Survey of medicinal cannabis use among childbearing women: Patterns of its use in pregnancy and retroactive self-assessment of its efficacy against ‘morning sickness’. Complement. Ther. Clin. Pract. 15, 242–246 (2009).

21. Gonzalez-Rosales, F. & Walsh, D. Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (Dronabinol). J. Pain Symptom Manage. 14, 311–314 (1997).

22. Green, S., Nathwani, D., Goldberg, D. & Kennedy, D. Nabilone as effective therapy for intractable nausea and vomiting in AIDS [letter]. Br. J. Clin. Pharmacol. 28, 494–495 (1989).

23. Dejesus, E., Rodwick, B. M., Bowers, D., Cohen, C. J. & Pearce, D. Use of dronabinol improves appetite and reverses weight loss in HIV/AIDS-infected patients. J. Int. Assoc. Physicians AIDS Care 6, 95–100 (2007).

24. Zutt, M., Hänßle, H., Emmert, S., Neumann, C. & Kretschmer, L. Dronabinol zur supportiven Therapie metastasierter maligner Melanome mit Lebermetastasen. Hautarzt 57, 423–427 (2006).

25. Volicer, L., Stelly, M., Morris, J., McLaughlin, J. & Volicer, B. J. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int. J. Geriatr. Psychiatry 12, 913–919 (1997).

26. Cooper, R. E. et al. Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial. Eur. Neuropsychopharmacol. 26, S130 (2016).

27. Aharonovich, E. et al. Concurrent cannabis use during treatment for comorbid ADHD and cocaine dependence: Effects on outcome. Am. J. Drug Alcohol Abuse 32, 629–635 (2006).

28. Hupli, A. M. M. Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland. Med. Cannabis Cannabinoids 1, 112–118 (2019).

29. Prentiss, D., Power, R., Balmas, G., Tzuang, G. & Israelski, D. M. Patterns of Marijuana Use among Patients with HIV/AIDS Followed in a Public Health Care Setting. J. Acquir. Immune Defic. Syndr. 35, 38–45 (2004).

30. Consroe, P. M. R. R. J. T. W. P. R. The Perceived Effects of Smoked Cannabis on Patients with Multiple Sclerosis. Eur. Neurol. (1997) doi:10.1159/000112901.

31. Linares, I. M. P. et al. No acute effects of Cannabidiol on the sleep-wake cycle of healthy subjects: A randomized, double-blind, placebo-controlled, crossover study. Front. Pharmacol. 9, 1–8 (2018).

32. Bonaccorso, S., Ricciardi, A., Zangani, C., Chiappini, S. & Schifano, F. Cannabidiol (CBD) use in psychiatric disorders: A systematic review. Neurotoxicology 74, 282–298 (2019).

33. Neubauer, D., Perkovic Benedik, M. & Osredkar, D. Cannabidiol for treatment of refractory childhood epilepsies: Experience from a single tertiary epilepsy center in Slovenia. Epilepsy Behav. 81, 79–85 (2018).

34. Devinsky, O. et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 15, 270–278 (2016).

35. Szaflarski, J. P. et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results. Epilepsia 59, 1540–1548 (2018).

36. Hausman-Kedem, M., Menascu, S. & Kramer, U. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents – An observational, longitudinal study. Brain Dev. 40, 544–551 (2018).